期刊
LANCET INFECTIOUS DISEASES
卷 12, 期 3, 页码 240-248出版社
ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(11)70318-8
关键词
-
资金
- Medical Research Council [MC_U117512723, MC_U117512708] Funding Source: Medline
- MRC [MC_U117512723, MC_U117512708] Funding Source: UKRI
- Medical Research Council [MC_U117512708, MC_U117512723] Funding Source: researchfish
Influenza A H1N1 2009 virus caused the first pandemic in an era when neuraminidase inhibitor antiviral drugs were available in many countries. The experiences of detecting and responding to resistance during the pandemic provided important lessons for public health, laboratory testing, and clinical management. We propose recommendations for antiviral susceptibility testing, reporting results, and management of patients infected with 2009 pandemic influenza A H1N1. Sustained global monitoring for antiviral resistance among circulating influenza viruses is crucial to inform public health and clinical recommendations for antiviral use, especially since community spread of oseltamivir-resistant A H1N1 2009 virus remains a concern. Further studies are needed to better understand influenza management in specific patient groups, such as severely immunocompromised hosts, including optimisation of antiviral treatment, rapid sample testing, and timely reporting of susceptibility results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据